Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-018"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-018"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0192
lpv:speaker	lp:Johannes Blokland2
lpv:spokenAs	unknown; ChristenUnie - Staatkundig Gereformeerde Parti (2002-03-18--2004-07-19)3 member; Delegation to the European Economic Area Joint Parliamentary Committee (EEA) (2002-02-07--2004-07-19)3 member; ECON (2002-01-17--2004-07-19)3 vice-chair; Delegation to the EU-Slovak Republic Joint Parliamentary Committee (2002-02-07--2004-04-30)3 co-chair; EDD (2001-01-30--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3
lpv:translated text	"Mr President, every human life is unique and valuable because it is a gift from God. Accordingly, every life deserves the best possible protection and care from the cradle to the grave. A smoothly running European medicines market fits in well with this ambition. Our group believes it to be of major importance that Europe does not present any obstacles which could frustrate the operation of the medicines market. We are therefore of the view that manufacturers of medicines must continue to have the choice between the centralised and decentralised registration of medicines. Compulsory centralised registration would hamper the necessary flexibility which regional products enjoy, it would lead to a brain drain from the national registration authorities and it could present too great a financial obstacle for SMEs, preventing them from introducing certain products onto the market. In addition, we are in favour of more research into the effects of medicines on children. To date, a large proportion of medicines administered to children has only been tested on adults, even though it is surely obvious that children are different from adults in terms of their metabolism, the necessary dosage and the administration method. Finally, we are against allowing medicines to be advertised, because this could lead to an unnecessary increase in the use of medicines. We are, however, in favour of providing patients with extensive information. We therefore await with interest the outcome of the trial proposed by the European Commission in which patients are actively provided with information."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph